BB-301: Dose escalation phase 1b cohort 1
BNTC-OPMD-BB-301-01
Phase 2 gene_therapy active
Quick answer
BB-301: Dose escalation phase 1b cohort 1 for Oculopharyngeal Muscular Dystrophy is a Phase 2 program (gene_therapy) at Benitec Biopharma with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Benitec Biopharma
- Indication
- Oculopharyngeal Muscular Dystrophy
- Phase
- Phase 2
- Modality
- gene_therapy
- Status
- active